Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis

American Journal of Physiology - Endocrinology and Metabolism

Volumn 284, Issue 5 47-5, 2003, Pages

  Pamir, Nathalie ^a   Lynn, Francis C ^a   Buchan, Alison M J ^a   Ehses, Jan ^a   Hinke, Simon A ^a   Pospisilik, J Andrew ^a   Miyawaki, Kazumasa ^b   Yamada, Yuichiro ^b   Seino, Yutaka ^b   McIntosh, Christopher H S ^a   Pederson, Raymond A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

CAMP; GLP 1; Incretin; Insulin; Pancreas perfusion

Indexed keywords

GLUCOSE; POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; IMPAIRED GLUCOSE TOLERANCE; INSULIN LIKE ACTIVITY; INSULIN METABOLISM; INSULIN RELEASE; INSULIN RESPONSE; MOUSE; NONHUMAN; NULL CELL; PANCREAS ISLET BETA CELL; PANCREAS PERFUSION; PRIORITY JOURNAL; STOMACH EMPTYING;

EID: 18244424871     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00270.2002     Document Type: Article

References (47)

1. Ahren B and Pacini G. Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice. Am J Physiol Endocrinol Metab 277: E996-E1004, 1999.
2. Baggio L, Kieffer TJ, and Drucker DJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice. Endocrinology 141: 3703-3709, 2000.
3. Creutzfeldt WOC, Orskov C, Kleine N, Holst JJ, Willms B, and Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide-1 (7-36) amide in type 1 diabetic patients. Diabetes Care 19: 580-586, 1996.
4. D'Alessio DA, Prigeon RL, and Ensinck JW. Enteral enhancement of glucose disposition by both insulin- dependent and isulin-independent process - a physiological role of glucagon-like peptide 1. Diabetes 44: 1433-1437, 1995.
5. Drucker DJ, Philippe J, Mojsov S, Chick WL, and Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cAMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84: 3434-3438, 1987.
6. Ebert R and Creutzfeldt W. Influence of gastric inhibitory polypeptide antiserum on glucose-induced insulin secretion in rats. Endocrinology 111: 1601-1606, 1982.
7. Ebert R, Illmer K, and Creutzfeldt W. Release of gastric inhibitory polypeptide (GIP) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP-antiserum in rats. Gastroenterology 76: 515-523, 1979.
8. Ebert R, Unger H, and Creutzfeldt W. Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption. Diabetologia 24: 449-454, 1983.
9. Ehses JA, Lee SST, Pederson RA, and McIntosh CHS. A new pathway for glucose-dependent insulinotropic polypeptide (GIP) receptor signaling - evidence for the involvement of phospholipase A, in GIP-stimulated insulin secretion. J Biol Chem 276: 23667-23673, 2001.
10. Ehses JA, Pelech SL, Pederson RA, and McIntosh CH. Glucose-dependent insulinotropic polypeptide activates the RafMek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J Biol Chem 277: 37088-37097, 2002.
11. Fehmann HC, Gherzi R, and Goke B. Regulation of islet hormone gene expression by incretin hormones. Exp Clin Endocrinol Diabetes 103: 56-65, 1995.
12. Freeman WM, Walker SJ, and Vrana KE. Quantitative RTPCR: pitfalls and potential. Biotechniques 26: 112-125, 1999.
13. Greenbaum C, Prigeon R, and D'Alessio D. Impaired β-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. Diabetes 51: 951-957, 2002.
14. Gutniak MK, Svartberg J, Hellstrom PM, Holst JJ, Adner N, and Ahren B. Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes. J Intern Med 250: 81-87, 2001.
15. Habener JF. The incretin notion and its relevance to diabetes. Endocrinol Metab Clin North Am 22: 775-794, 1993.
16. Hiroyoshi M, Tateishi K, Yasunami Y, Maeshiro K, Ono J, Matsuoka Y, and Ikeda S. Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes. Am J Gastroenterol 94: 976-981, 1999.
17. Holst JJ. Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential. Curr Med Chem 6: 1005-1017, 1999.
18. Holst JJ, Gromada J, and Nauck MA. The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 40: 984-986, 1997.
19. Holz GG and Leech CA. Glucagon-like peptide-1: an insulinotropic hormone with potent growth factor actions at the pancreatic islets of Langerhans. Molecular Basis of Pancreas Development and Function, edited by Habener JF and Hussain MA. Norwell, MA: Kluwer Academic, 2001, p. 109-141.
20. Kieffer TJ and Habener JF. The glucagon-like peptides. Endocr Rev 20: 876-913, 1999.
21. Krarup T, Saurbrey N, Moody AJ, Kuhl C, and Madsbad S. Effect of porcine gastric inhibitory polypeptide on β-cell function in type I and type II diabetes mellitus. Metabolism 36: 677-682, 1984.
22. Lewis JT, Dayanandan B, Habener JF, and Kieffer TJ. Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist. Endocrinology 141: 3710-3716, 2000.
23. Ling Z, Wu D, Zambre Y, Flamez D, Drucker DJ, Pipeleers DG, and Schuit FC. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch 438: 382-387, 2001.
24. Lynn FC, Pamir N, Ng EHC, McIntosh CHS, Kieffer TJ, and Pederson RA. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 50: 1004-1011, 2001.
25. McIntosh CH, Wheeler MB, Gelling RW, Brown JC, and Pederson RA. GIP receptors and signal-transduction mechanisms. Acta Physiol Scand 157: 361-365, 1996.
26. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J, and Seino Y. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 96: 14843-14847, 1999.
27. Moens K, Heimberg H, Flamez D, Huypens P, Quartier E, Ling Z, Pipeleers D, Gremlich S, Thorens B, and Schuit F. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 45: 257-261, 1996.
28. Nauck M, Stockmann F, Ebert R, and Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29: 46-52, 1986.
29. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, and Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301-307, 1993.
30. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, and Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492-498, 1986.
31. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, and Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273: E981-E988, 1997.
32. Orskov C, Jeppesen J, Madsbad S, and Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87: 415-423, 1991.
33. Pederson RA, Satkunarajah M, McIntosh CHS, Scrocchi LA, Flamez D, Schuit F, Drucker DJ, and Wheeler MB. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor (-/-) mice. Diabetes 47: 1046-1052, 1998.
34. Pederson RA, Schubert HE, and Brown JC. The insulinotropic action of gastric inhibitory polypeptide. Can J Physiol Pharmacol 53: 217-223, 1975.
35. Pospisilik JA, Stafford SG, Demuth H-U, Brownsey R, Parkhouse W, Finegood DT, McIntosh CHS, and Pederson RA. Long-term treatment with dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 51: 943-950, 2002.
36. Sandhu H, Wiesenthal SR, MacDonald PE, McCall RH, Tchipashvili V, Rashid S, Satkunarajah M, Irwin DM, Shi ZQ, Brubaker PL, Wheeler MB, Vranic M, Efendic S, and Giacca A. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 48: 1045-1053, 1999.
37. Scrocchi LA, Brown TJ, Maclusky N, Brubaker PL, Auerbach AB, Joyner AL, and Drucker DJ. Glucose intolerance but normal satiety in mice with null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2: 1254-1258, 1996.
38. Trumper A, Trumper K, and Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in β(INS-1)-cells. J Endocrinol 174: 233-246, 2002.
39. Trumper A, Trumper K, Trusheim H, Arnold R, Goke B, and Horsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for β (INS-1) cells by pleiotropic signaling. Mol Endocrinol 15: 1559-1570, 2001.
40. Tseng CC, Kieffer TJ, Jarboe LA, Usdin TB, and Wolfe MM. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Invest 98: 2440-2445, 1996.
41. Tseng CC, Zhang XY, and Wolfe MM. Effect of GIP and GLP-1 antagonists on insulin release in the rat. Am J Physiol Endocrinol Metab 276: E1049-E1054, 1999.
42. Unger RH and Eisentraut AM. Entero-insular axis. Arch Intern Med 123: 261-266, 1969.
43. Vaag A, Holst J, Volund A, and Beck-Nielsen H. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM) - evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 135: 425-432, 1996.
44. Vilsboll T, Krarup T, Madsbad S, and Holst J. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45: 1111-1119, 2002.
45. Ward WK, Beard JC, and Porte DJ. Clinical aspects of islet β cell function in non-insulin-dependent diabetes mellitus. Diabetes Metab Res Rev 2: 297-312, 1986.
46. Wheeler MB, Gelling RW, McIntosh CH, Georgiou J, Brown JC, and Pederson RA. Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties. Endocrinology 136: 4629-4639, 1995.
47. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, and Nauck MA. Gastric empying glucose responses, and insulin secretion after a liquid test meal - effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin dependent) diabetic patients. J Clin Endocrinol Metab 81: 327-332, 1996.